Celebrating the Approval of Ruoxinlin®, China’s First Class 1 New Antidepressant!

On November 11, Luye Pharma Group’s management team and employees got together to celebrate the approval of Ruoxinlin® (Toludesvenlafaxine Hydrochloride Extended-Release Tablets), its Class 1 new antidepressant, for launch in China. The celebration took place in Shanghai and Beijing parallelly, and was made available for live streaming to people throughout Luye Life Sciences Group. Employees in different places watched the celebration live to witness the milestone together. 

Ruoxinlin® is China’s first Class 1 innovative drug for treating depression developed by a local company with IP protection. Its launch represents a major breakthrough for a local innovative drug in this field, and will take Luye Pharma to a new level.

Liu Dianbo, Chairman of Luye Pharma Group, congratulated the launch of Ruoxinlin® at the event, saying: "It’s been 12 years from the pre-clinical study of Ruoxinlin® to its launch, a marathon that’s really not easy. We’ve put a lot of effort into it, to get such a valuable result today. My special thanks go to Luye scientists. I also thank the project team for their perseverance and all other teams for their collaboration."

He added: "This is our fourth celebration in two years. Despite the significant challenge of COVID-19, we’ve really ushered in a harvest season. The launch of Ruoxinlin® as a Class 1 new drug has again proved the value of our R&D system. Our journey of R&D over the past ten-plus years has demonstrated our mission of providing ‘Advanced Technologies for Better Quality of Life’. We’ll have more than 10 new drugs to be approved in the next three years.”

Celebrating China’s First Denosumab Biosimilar Boyoubei® Approved for Launch by NMPA

On November 18, leaders and employees from Boan Biotech and Luye Pharma Group gathered together to celebrate the company's self-developed first-line drug for osteoporosis -- Boyoubei ®, the first domestic disuzumab injection.

From the formal establishment of the project in November 2014 to the official approval on November 8, 2022, the hard work and struggle in the project are vividly remembered. Each step embodies the wisdom and dedication of the team members. From R & D to production to registration, all the teams go all out, day and night, after eight years of relay running, accelerated promotion, with action to interpret the passion and speed of Boan Biotech.

Liu Dianbo, Chairman of the Group, shared the development history of the Group from nothing to enter the field of macromolecular biological drugs at the ceremony, highly affirming the scientific spirit of the Boan team to work hard, innovate and explore. Warmly congratulating Boyoubei ® as the world's first dizumab biosimilar drug approved for the market, and expressing heartfelt thanks to all those who have contributed to the project!